EMP1 is also a biomarker of gefitinib resistance, and it has been linked to a lack of complete or partial response to gefitinib in lung cancer patient samples, as well as clinical progression to secondary gefitinib resistance [35]. The gene discussed is EMP1; the disease is lung carcinoma.